Seminars in Perinatology
Volume 32, Issue 5 , Pages 350-354 , October 2008

Fetal and Neonatal Effects of Maternal Drug Treatment for Depression

  • Jaques Belik, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Jaques Belik, MD, Professor of Pediatrics and Physiology, University of Toronto, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, M5G 1X8 Canada

References 

  1. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008;358:55–68
  2. World Health Organization. www.whoint/mental_health/management/depression/definition/en2008;
  3. Vasiliadis HM, Lesage A, Adair C, et al. Do Canada and the United States differ in prevalence of depression and utilization of services?. Psychiatr Serv. 2007;58:63–71
  4. Merikangas KR, Ames M, Cui L, et al. The impact of comorbidity of mental and physical conditions on role disability in the US adult household population. Arch Gen Psychiatry. 2007;64:1180–1188
  5. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–3105
  6. Austin MP, Kildea S, Sullivan E. Maternal mortality and psychiatric morbidity in the perinatal period: challenges and opportunities for prevention in the Australian setting. Med J Aust. 2007;186:364–367
  7. Lattimore KA, Donn SM, Kaciroti N, et al. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol. 2005;25:595–604
  8. Austin MP. To treat or not to treat: maternal depression. SSRI use in pregnancy and adverse neonatal effects. Psychol Med. 2006;36:1663–1670
  9. Andrade SE, Raebel MA, Morse AN, et al. Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf. 2006;15:546–554
  10. Lawrenson RA, Tyrer F, Newson RB, et al. The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord. 2000;59:149–157
  11. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf. 2005;14:823–827
  12. Rahimi R, Nikfar S, Abdollahi M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod Toxicol. 2006;22:571–575
  13. Hendrick V, Stowe ZN, Altshuler LL, et al. Placental passage of antidepressant medications. Am J Psychiatry. 2003;160:993–996
  14. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010–1015
  15. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA. 1998;279:609–610
  16. Ortiz J, Artigas F. Effects of monoamine uptake inhibitors on extracellular and platelet 5-hydroxytryptamine in rat blood: different effects of clomipramine and fluoxetine. Br J Pharmacol. 1992;105:941–946
  17. Alvarez JC, Sanceaume M, Advenier C, et al. Differential changes in brain and platelet 5-HT concentrations after steady-state achievement and repeated administration of antidepressant drugs in mice. Eur Neuropsychopharmacol. 1999;10:31–36
  18. Alvarez JC, Gluck N, Arnulf I, et al. Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine. Clin Pharmacol Ther. 1999;66:617–624
  19. Fornaro E, Li D, Pan J, et al. Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am J Respir Crit Care Med. 2007;176:1035–1040
  20. Morrison JL, Chien C, Riggs KW, et al. Effect of maternal fluoxetine administration on uterine blood flow, fetal blood gas status, and growth. Pediatr Res. 2002;51:433–442
  21. Morrison JL, Chien C, Gruber N, et al. Fetal behavioural state changes following maternal fluoxetine infusion in sheep. Brain Res Dev Brain Res. 2001;131:47–56
  22. Morrison JL, Riggs KW, Chien C, et al. Chronic maternal fluoxetine infusion in pregnant sheep: effects on the maternal and fetal hypothalamic-pituitary-adrenal axes. Pediatr Res. 2004;56:40–46
  23. Morrison JL, Riggs KW, Rurak DW. Fluoxetine during pregnancy: impact on fetal development. Reprod Fertil Dev. 2005;17:641–650
  24. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354:579–587
  25. de Caestecker M. Serotonin signaling in pulmonary hypertension. Circ Res. 2006;98:1229–1231
  26. Guignabert C, Raffestin B, Benferhat R, et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation. 2005;111:2812–2819
  27. Marcos E, Adnot S, Pham MH, et al. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med. 2003;168:487–493
  28. Kawut SM, Horn EM, Berekashvili KK, et al. Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther. 2006;19:370–374
  29. Hernandez-Diaz S, Van Marter LJ, Werler MM, et al. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics. 2007;120:e272–e282
  30. Ghamra ZW, Dweik RA. Primary pulmonary hypertension: an overview of epidemiology and pathogenesis. Cleve Clin J Med. 2003;70:S2–S8(suppl 1)
  31. Smith AM, Jones RD, Channer KS. The influence of sex hormones on pulmonary vascular reactivity: possible vasodilator therapies for the treatment of pulmonary hypertension. Curr Vasc Pharmacol. 2006;4:9–15
  32. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293:2372–2383
  33. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160:173–176
  34. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63:898–906
  35. Gentile S, Rossi A, Bellantuono C. SSRIs during breastfeeding: spotlight on milk-to-plasma ratio. Arch Womens Ment Health. 2007;10:39–51
  36. Brandon AR, Trivedi MH, Hynan LS, et al. Prenatal depression in women hospitalized for obstetric risk. J Clin Psychiatry. 2008;69:635–643
  37. Qiu C, Sanchez SE, Lam N, et al. Associations of depression and depressive symptoms with preeclampsia: results from a Peruvian case-control study. BMC Womens Health. 2007;7:15
  38. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression (Development of the 10-item Edinburgh Postnatal Depression Scale). Br J Psychiatry. 1987;150:782–786
  39. Sanderson CA, Cowden B, Hall DM, et al. Is postnatal depression a risk factor for sudden infant death?. Br J Gen Pract. 2002;52:636–640

PII: S0146-0005(08)00086-4

doi: 10.1053/j.semperi.2008.08.001

Seminars in Perinatology
Volume 32, Issue 5 , Pages 350-354 , October 2008

Article Tools

* Image Usage & Resolution